Lima, Ana RitaPinto, JoanaBastos, Maria de LourdesCarvalho, MárciaGuedes de Pinho, Paula2021-07-022021-07-0220181573-3882http://hdl.handle.net/10284/10018Prostate cancer (PCa) is one of the most prevalent cancers in men worldwide. Serum prostate-specific antigen (PSA) remains the most used biomarker in the detection and management of patients with PCa, in spite of the problems related with its low specificity, false positive rate and overdiagnosis. Furthermore, PSA is unable to discriminate indolent from aggressive PCa, which can lead to overtreatment. Early diagnosed and treated PCa can have a good prognosis and is potentially curable. Therefore, the discovery of new biomarkers able to detect clinically significant aggressive PCa is urgently needed.engProstate cancerMetabolomicsTissuesNuclear magnetic resonance spectroscopyjournal article10.1007/s11306-018-1384-2